Overview

* PMV Pharmaceuticals ( PMVP ) reports Q3 net loss of $21.1 mln, driven by increased R&D costs

* Company ends Q3 with $129.3 mln in cash, runway until Q1 2027

* Clinical study shows 34% ORR across cohorts, 46% in ovarian cancer

Outlook

* PMV Pharma plans NDA submission for rezatapopt in Q1 2027

* Company expects cash runway to end of Q1 2027

Result Drivers

* R&D EXPENSES - Increased R&D costs due to advancement of rezatapopt program

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.40

Q3 Net -$21.06

Income mln

Q3 $22.52

Operatin mln

g

Expenses

Q3 -$22.52

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for PMV Pharmaceuticals Inc ( PMVP ) is $6.50, about 79.5% above its November 11 closing price of $1.33

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)